Provided by Tiger Trade Technology Pte. Ltd.

OPUS GENETICS INC

5.73
+1.3932.03%
Pre-market: 5.940.2090+3.65%05:29 EDT
Volume:54.32M
Turnover:331.75M
Market Cap:476.71M
PE:-4.43
High:7.07
Open:5.31
Low:5.31
Close:4.34
52wk High:7.07
52wk Low:1.32
Shares:83.20M
Float Shares:65.21M
Volume Ratio:18.35
T/O Rate:83.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2925
EPS(LYR):-0.8000
ROE:-4796.52%
ROA:-48.06%
PB:-36.71
PE(LYR):-7.16

Loading ...

Opus Genetics - Files for Resale of up to 2.68 Mln Shares of Common Stock by Selling Stockholders - SEC Filing

THOMSON REUTERS
·
Jun 06

Opus Genetics Initiated at Buy by Guggenheim

Dow Jones
·
Jun 04

Guggenheim Initiates Opus Genetics at Buy With $16 Price Target

MT Newswires Live
·
Jun 04

Opus Genetics publishes investor presentation on gene therapy pipeline for rare inherited retinal diseases

Reuters
·
Jun 02

BRIEF-Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule

Reuters
·
May 29

Opus Genetics grants options for 698,000 shares to 10 new hires under inducement plan

Reuters
·
May 29

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 29

Opus Genetics presents at Jefferies Global Healthcare Conference

Reuters
·
May 27

Opus Genetics Initiated at Outperform by Leerink Partners

Dow Jones
·
May 21

Leerink Partners Initiates Opus Genetics at Outperform With $10 Price Target

MT Newswires Live
·
May 21

Opus Genetics initiated with an Outperform at Leerink

TIPRANKS
·
May 21

Opus Genetics Inc : Leerink Partners Initiates Coverage With Outperform Rating; Target Price $10

THOMSON REUTERS
·
May 21

Foundation Fighting Blindness Retinal Degeneration Fund sells Opus Genetics shares worth $7.4 million

Reuters
·
May 21

LifeSci Capital Sticks to Its Buy Rating for Opus Genetics (IRD)

TIPRANKS
·
May 16

Cantor Fitzgerald Sticks to Its Buy Rating for Opus Genetics (IRD)

TIPRANKS
·
May 14

Opus Genetics (IRD) Q1 Loss Of US$65.5 Million Intensifies Bearish Community Narratives

Simply Wall St.
·
May 14

Opus Genetics Is Maintained at Market Outperform by Citizens

Dow Jones
·
May 13

Opus Genetics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Opus Genetics to present at RBC Capital Markets Global Healthcare Conference

Reuters
·
May 13

Opus Genetics price target lowered to $11 from $12 at Citizens

TIPRANKS
·
May 13